No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30days course of nitazoxanide monotherapy.

LAUFER N; ABUSAMRA L; BOLCIC F; GUN A; ROLÓN MJ; PÉREZ H; KROLEWIECKI A; SALOMÓN H; QUARLERI J; CAHN P

ANTIVIRAL RESEARCH

ELSEVIER SCIENCE BV

Lugar: Filadelfia; Año: 2011 vol. 92 p. 497 - 499

0166-3542

There are two new drugs approved and several in development for treatment of chronic HCV; among them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during treatment in none of the patients evaluated. This data suggests that despite the promising results reported for HCV genotype 4 mono-infected patients, NTZ exhibit poor activity as monotherapy in HIV/HCV co-infected patients with genotype 1.